Brent Wood, MD, PhD

Title(s)Professor of Pathology (Clinical Scholar)
SchoolKeck School of Medicine of Usc
Address4640 West Sunset Blvd
Off Campus
Los Angeles CA 90027
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. Haematologica. 2024 Feb 01; 109(2):401-410. Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH, Schmidt E, Valentine Iii CC, Salk JJ, Wood BL, Erba HP, Radich JP, Hourigan CS. PMID: 37534515; PMCID: PMC10828764.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    2. Maturational dyssynchrony in benign B-cell precursors following lymphocyte depleting chemotherapy: A potential pitfall for B-lymphoblastic leukemia minimal/measurable residual disease (MRD) flow cytometry analysis. Cytometry B Clin Cytom. 2024 03; 106(2):138-141. Placek A, Lockhart B, Miller KP, Wertheim GB, Maude SL, Wood BL, Kovach AE. PMID: 38247200.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078. Wood BL, Devidas M, Summers RJ, Chen Z, Asselin B, Rabin KR, Zweidler-McKay PA, Winick NJ, Borowitz MJ, Carroll WL, Raetz EA, Loh ML, Hunger SP, Dunsmore KP, Teachey DT, Winter SS. PMID: 37556734; PMCID: PMC10862241.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    4. Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis. Semin Diagn Pathol. 2023 Nov; 40(6):457-471. Kovach AE, Wood BL. PMID: 37953192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748. Leukemia. 2023 Sep; 37(9):1944-1951. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Oliveira Araujo IB, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Di Napoli A, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Suzuki R, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W, International Agency for Research on Cancer/World Health Organization. PMID: 37468552; PMCID: PMC10457187.
      View in: PubMed   Mentions:    Fields:    
    6. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. medRxiv. 2023 Mar 27. Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH, Schmidt E, Valentine CC, Salk JJ, Wood BL, Erba HP, Radich JP, Hourigan CS. PMID: 37034683; PMCID: PMC10081409.
      View in: PubMed   Mentions:
    7. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023 02 28; 7(4):575-585. Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard J, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. PMID: 35482927; PMCID: PMC9979750.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    8. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Haematologica. 2023 02 01; 108(2):420-432. Orvain C, Wilson JA, Fang M, Sandmaier BM, Rodríguez-Arbolí E, Wood BL, Othus M, Appelbaum FR, Walter RB. PMID: 35924583; PMCID: PMC9890022.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    9. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023 Feb; 10(2):e129-e141. Gupta S, Dai Y, Chen Z, Winestone LE, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano LA, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guest EM, Dunsmore KP, Kairalla JA, Winick NJ, Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas M. PMID: 36725118; PMCID: PMC9951049.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    10. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer. 2022 11; 69(11):e29901. Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, Attarbaschi A, Brown PA, Gardner RA, Gaynon PS, Hutchinson R, Huynh VT, Jeha S, Marcus L, Messinger Y, Schultz KR, Cassar J, Locatelli F, Zwaan CM, Wood BL, Sposto R, Gore L. PMID: 35989458.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 07; 36(7):1720-1748. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. PMID: 35732829; PMCID: PMC9214472.
      View in: PubMed   Mentions: 519     Fields:    Translation:Humans
    12. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 07 01; 40(19):2106-2118. Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. PMID: 35271306; PMCID: PMC9242409.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCellsCTClinical Trials
    13. Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method. Curr Protoc. 2022 Mar; 2(3):e383. Borowitz MJ, Wood BL, Keeney M, Hedley BD. PMID: 35263042.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022 05 01; 128(9):1863-1870. Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC, Maloney KW, Mattano LA, Winter SS, Carroll AJ, Heerema NA, Borowitz MJ, Wood BL, Carroll WL, Raetz EA, Winick NJ, Loh ML, Hunger SP, Devidas M. PMID: 35201611; PMCID: PMC9007837.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. Hemasphere. 2022 Jan; 6(1):e676. Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, Walter RB, Wood BL, Roumier C, Philippé J, Denys B, Jorgensen JL, Bene MC, Lacombe F, Plesa A, Guzman ML, Wierzbowska A, Czyz A, Ngai LL, Schwarzer A, Bachas C, Cloos J, Subklewe M, Fuering-Buske M, Buccisano F. PMID: 34964040; PMCID: PMC8701786.
      View in: PubMed   Mentions: 20  
    16. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. J Clin Oncol. 2022 03 20; 40(9):932-944. Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. PMID: 34767461; PMCID: PMC8937010.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    17. Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2021 04 06; 113(4):408-417. Zhang H, Liu AP, Devidas M, Lee SH, Cao X, Pei D, Borowitz M, Wood B, Gastier-Foster JM, Dai Y, Raetz E, Larsen E, Winick N, Bowman WP, Karol S, Yang W, Martin PL, Carroll WL, Pui CH, Mullighan CG, Evans WE, Cheng C, Hunger SP, Relling MV, Loh ML, Yang JJ. PMID: 32894760; PMCID: PMC8680540.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    18. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929. Rau RE, Dai Y, Devidas M, Rabin KR, Zweidler-McKay P, Angiolillo A, Schore RJ, Burke MJ, Salzer WL, Heerema NA, Carroll AJ, Winick NJ, Hunger SP, Raetz EA, Loh ML, Wood BL, Borowitz MJ. PMID: 33559396; PMCID: PMC8808711.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    19. Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. Blood. 2021 01 28; 137(4):569-572. Godwin CD, Zhou Y, Othus M, Asmuth MM, Shaw CM, Gardner KM, Wood BL, Walter RB, Estey EH. PMID: 33507294; PMCID: PMC7845008.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    20. Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatr Blood Cancer. 2021 01; 68(1):e28574. Shah NN, Schneiderman J, Kuruvilla D, Bhojwani D, Fry TJ, Martin PL, Schultz KR, Silverman LB, Whitlock JA, Wood B, Vainshtein I, Adams A, Confer D, Pulsipher MA, Chaudhury S, Wayne AS. PMID: 32959985.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers (Basel). 2020 Aug 19; 12(9). Morsink LM, Sandmaier BM, Othus M, Palmieri R, Granot N, Bezerra ED, Wood BL, Mielcarek M, Schoch G, Davis C, Flowers MED, Deeg HJ, Appelbaum FR, Storb R, Walter RB. PMID: 32825022; PMCID: PMC7565021.
      View in: PubMed   Mentions: 16  
    22. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. Curr Protoc Cytom. 2020 06; 93(1):e73. Wood BL. PMID: 32311834.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    23. Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. Leukemia. 2020 06; 34(6):1577-1587. Morsink LM, Othus M, Bezerra ED, Wood BL, Fang M, Sandmaier BM, Mielcarek M, Schoch G, Storb R, Deeg HJ, Appelbaum FR, Walter RB. PMID: 31974434; PMCID: PMC7272254.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    24. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. Blood Rev. 2020 09; 43:100650. Bewersdorf JP, Shallis RM, Boddu PC, Wood B, Radich J, Halene S, Zeidan AM. PMID: 31883804.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    25. Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia. 2020 06; 34(6):1701-1705. Morsink LM, Bezerra ED, Othus M, Wood BL, Fang M, Sandmaier BM, Mielcarek MB, Deeg HJ, Schoch G, Appelbaum FR, Walter RB. PMID: 31796913; PMCID: PMC7266710.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    26. Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Bone Marrow Transplant. 2020 03; 55(3):669-672. Hoffmann AP, Besch AL, Othus M, Morsink LM, Wood BL, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. PMID: 31685932.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    27. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer. 2020 02 01; 126(3):593-601. Orgel E, Alexander TB, Wood BL, Kahwash SB, Devidas M, Dai Y, Alonzo TA, Mullighan CG, Inaba H, Hunger SP, Raetz EA, Gamis AS, Rabin KR, Carroll AJ, Heerema NA, Berman JN, Woods WG, Loh ML, Zweidler-McKay PA, Horan JT, Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. PMID: 31661160; PMCID: PMC7489437.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    28. Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma. Cytometry B Clin Cytom. 2019 07; 96(4):256-265. DiGiuseppe JA, Wood BL. PMID: 31231940.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    29. Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. JNCI Cancer Spectr. 2018 Oct; 2(4):pky069. Galimberti S, Devidas M, Lucenti A, Cazzaniga G, Möricke A, Bartram CR, Mann G, Carroll W, Winick N, Borowitz M, Wood B, Basso G, Conter V, Zimmermann M, Suciu S, Biondi A, Schrappe M, Hunger SP, Valsecchi MG. PMID: 31360884; PMCID: PMC6649800.
      View in: PubMed   Mentions: 7     Fields:    
    30. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1. Cytometry B Clin Cytom. 2019 01; 96(1):67-72. Zhou Y, Moon A, Hoyle E, Fromm JR, Chen X, Soma L, Salipante SJ, Wood BL, Wu D. PMID: 30417521.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    31. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018 10 10; 36(29):2926-2934. Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP. PMID: 30138085; PMCID: PMC6366301.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    32. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 2018 08 01; 36(22):2306-2314. Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, Chang BH, Mullighan C, Iacobucci I, Silverman LB, Borowitz MJ, Carroll AJ, Heerema NA, Gastier-Foster JM, Wood BL, Mizrahy SL, Merchant T, Brown VI, Sieger L, Siegel MJ, Raetz EA, Winick NJ, Loh ML, Carroll WL, Hunger SP. PMID: 29812996; PMCID: PMC6067800.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCTClinical Trials
    33. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. Am J Hematol. 2018 08; 93(4):546-552. Cassaday RD, Stevenson PA, Wood BL, Becker PS, Hendrie PC, Sandmaier BM, Radich JL, Shustov AR. PMID: 29318644.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018 03 22; 131(12):1275-1291. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. PMID: 29330221; PMCID: PMC5865231.
      View in: PubMed   Mentions: 396     Fields:    Translation:Humans
    35. Methods of Detection of Measurable Residual Disease in AML. Curr Hematol Malig Rep. 2017 12; 12(6):557-567. Zhou Y, Wood BL. PMID: 29098609.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    36. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol. 2017 Jul 13; 3(7):e170580. Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP. PMID: 28494052; PMCID: PMC5824235.
      View in: PubMed   Mentions: 171     Fields:    Translation:Humans
    37. Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. Haematologica. 2017 09; 102(9):1549-1557. Waalkes A, Penewit K, Wood BL, Wu D, Salipante SJ. PMID: 28572161; PMCID: PMC5685235.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    38. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017 05; 102(5):865-873. Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB. PMID: 28126965; PMCID: PMC5477605.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    39. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. Blood Rev. 2017 03; 31(2):63-75. Chen X, Wood BL. PMID: 27742133.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    40. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometry B Clin Cytom. 2018 01; 94(1):112-120. Cherian S, Miller V, McCullouch V, Dougherty K, Fromm JR, Wood BL. PMID: 27598971.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    41. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):1974-1982. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. PMID: 27544285; PMCID: PMC5072749.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    42. A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. J Pediatr Hematol Oncol. 2016 08; 38(6):409-17. Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE. PMID: 27299599; PMCID: PMC4955695.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. J Clin Oncol. 2016 07 10; 34(20):2380-8. Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, Mattano LA, Cole C, Eicher A, Haugan M, Sorenson M, Heerema NA, Carroll AA, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Winick NJ, Hunger SP, Carroll WL. PMID: 27114587; PMCID: PMC4981974.
      View in: PubMed   Mentions: 163     Fields:    Translation:Humans
    44. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2016 09; 57(9):2109-18. Cassaday RD, Alan Potts D, Stevenson PA, Bar M, Georges GE, Shustov AR, Sorror ML, Wood BL, Delaney C, Doney KC, Storb RF, Sandmaier BM. PMID: 27002921; PMCID: PMC5010422.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    45. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? J Clin Oncol. 2016 Feb 01; 34(4):329-36. Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. PMID: 26668349; PMCID: PMC4872033.
      View in: PubMed   Mentions: 173     Fields:    Translation:Humans
    46. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1258-64. Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, Sandhu VK, Abkowitz JL, Appelbaum FR, Estey EH. PMID: 25732155.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCells
    47. Apparent CD19 expression by natural killer cells: a potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia. Cytometry B Clin Cytom. 2015 Mar; 88(2):145-7. Soma L, Wu D, Chen X, Edlefsen K, Fromm JR, Wood B. PMID: 25091590.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    48. Apparent CD19 expression by natural killer cells: A potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia. Cytometry B Clin Cytom. 2014 Jul 21. Soma L, Wu D, Chen X, Edlefsen K, Fromm JR, Wood B. PMID: 25046149.
      View in: PubMed   Mentions:    Fields:    
    49. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014 Sep 01; 20(17):4540-8. Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, Vogt J, Rieder M, Kirsch I, Carlson C, Williamson D, Wood BL, Robins H. PMID: 24970842; PMCID: PMC5142743.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    50. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Mod Pathol. 2014 Nov; 27(11):1438-46. Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D. PMID: 24743218; PMCID: PMC4201902.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    51. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment. 2014; 2014:421723. Bar M, Wood BL, Radich JP, Doney KC, Woolfrey AE, Delaney C, Appelbaum FR, Gooley TA. PMID: 24778882; PMCID: PMC3981457.
      View in: PubMed   Mentions: 38  
    52. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. J Clin Oncol. 2013 Sep 20; 31(27):3397-402. Heerema NA, Carroll AJ, Devidas M, Loh ML, Borowitz MJ, Gastier-Foster JM, Larsen EC, Mattano LA, Maloney KW, Willman CL, Wood BL, Winick NJ, Carroll WL, Hunger SP, Raetz EA. PMID: 23940221; PMCID: PMC3770866.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    53. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013 Sep 05; 122(10):1813-21. Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP, Estey EH, Appelbaum FR. PMID: 23847197; PMCID: PMC3765060.
      View in: PubMed   Mentions: 148     Fields:    Translation:Humans
    54. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med. 2012 May 16; 4(134):134ra63. Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, Greisman HA, Sabath DE, Wood BL, Robins H. PMID: 22593176.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansCells
    55. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011 Mar 20; 29(9):1190-7. Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW, Gopal AK, Appelbaum FR, Pagel JM. PMID: 21282535; PMCID: PMC3083874.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    56. Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. Cytometry B Clin Cytom. 2010 May; 78(3):139-46. Roshal M, Fromm JR, Winter S, Dunsmore K, Wood BL. PMID: 20155852; PMCID: PMC3025860.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans